about
Adrenocortical tumors in Italian children: analysis of clinical characteristics and P53 status. Data from the national registries.Successful treatment with the monoclonal antibody rituximab in two children with refractory autoimmune thrombocytopenia.Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.Persistent B-cell depletion after rituximab for thrombocytopenic purpura.The role of Helicobacter pylori in children with chronic idiopathic thrombocytopenic purpura.Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response.Thrombocytopenia and splenomegaly: an unusual presentation of congenital hepatic fibrosis.Effect of eradication of Helicobacter pylori in children with chronic immune thrombocytopenia: a prospective, controlled, multicenter study.Infantile fibrosarcoma: management based on the European experience.Hyper-activation of Notch3 amplifies the proliferative potential of rhabdomyosarcoma cells.Paratesticular desmoplastic small round cell tumor: case report and review of the literature.NELL1, whose high expression correlates with negative outcomes, has different methylation patterns in alveolar and embryonal rhabdomyosarcomaDesmoplastic small round cell tumour in children and adolescents.Alveolar soft part sarcoma in children and adolescents: A report from the Soft-Tissue Sarcoma Italian Cooperative Group.Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups.Epithelioid sarcoma in children and adolescents: a report from the Italian Soft Tissue Sarcoma Committee.Ewing sarcoma of the bone in children under 6 years of ageNeoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1.Salvage rates and prognostic factors after relapse in children and adolescents with initially localised synovial sarcoma.Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups.Management of childhood malignant peripheral nerve sheath tumor.Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005).Biopsy or debulking surgery as initial surgery for locally advanced rhabdomyosarcomas in children?: the experience of the Italian Cooperative Group studies.Epithelial thymic tumours in paediatric age: a report from the TREP projectForeign children with cancer in Italy.High IGFBP2 expression correlates with tumor severity in pediatric rhabdomyosarcoma.Ovarian Sertoli Leydig cell tumours in children and adolescents: an analysis of the European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT).MicroRNA-27a Contributes to Rhabdomyosarcoma Cell Proliferation by Suppressing RARA and RXRA.DAX-1 Expression in Pediatric Rhabdomyosarcomas: Another Immunohistochemical Marker Useful in the Diagnosis of Translocation Positive Alveolar Rhabdomyosarcoma.Conservative strategy in infantile fibrosarcoma is possible: The European paediatric Soft tissue sarcoma Study Group experience.Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.Global DNA methylation profiling uncovers distinct methylation patterns of protocadherin alpha4 in metastatic and non-metastatic rhabdomyosarcoma.Grossly-resected synovial sarcoma treated by the German and Italian Pediatric Soft Tissue Sarcoma Cooperative Groups: discussion on the role of adjuvant therapies.A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases.Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups.High ALK mRNA expression has a negative prognostic significance in rhabdomyosarcoma.Parameningeal rhabdomyosarcoma in pediatric age: results of a pooled analysis from North American and European cooperative groups.Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.Towards a Model-Based Dose Recommendation for Doxorubicin in Children.
P50
Q30844303-3CD31888-D0D2-4BFD-87F8-A52CFD9DEB8CQ33362441-E8BE784E-18C4-405C-A7D9-30027B158930Q33372069-7C4353A6-D1DF-48B4-B1BE-B32F164B59ABQ33372202-7C33B1A4-8377-4134-B209-E9B9E84FFB2BQ33378166-A12168A5-4076-4EEE-9997-D90456302452Q33382172-6CEA606D-2AED-4EA7-AFBE-780AE3A2FA71Q33389109-0CD859EF-1FDB-4774-BB84-402EEEE3A3D3Q33391827-28AC48D8-4937-4A3D-8226-F4096E2E6F54Q33516050-FD3AA7C3-894A-4BF4-BDB4-2F636CE30829Q33567866-8FBCDA4D-592F-42CC-B8E0-8A4CD72E3AA2Q33707222-CB5448FF-4F3E-415E-9911-0BC77057E2DAQ33779367-50A1581F-2BC0-440C-90E1-6BF844CA5FAEQ33910472-D150C0A3-9134-4FA6-ABB6-612E88CB1E4AQ34121090-B6DAFD8F-B604-4953-B0FE-FF2194D15616Q34154064-60E7354D-9A14-4740-8FDF-0F4BC22309C1Q34476210-777E2D7A-1AF3-4843-90AA-1B1B5A57A0C7Q34575191-FB7583ED-054A-4C5E-8DB4-E689CC6CE7E9Q34638074-BCA85892-7389-45F8-B042-F7E621F176FDQ34640862-0D503B73-CFAC-4AC9-90DD-6F330A7D3AFDQ34654311-1E81C2CD-9FFE-4E07-87AD-C04F9DF7DA8EQ34664326-486106B8-B283-400C-9419-935B757DC94DQ34666948-FC1B6F76-23E7-49DA-ABE8-EF97C34B713EQ34701898-CC7FBFE2-E460-437B-A243-2BD1BD4F3519Q35068070-677F6A0B-0E1D-458D-8C04-447D28BF87F6Q35293935-C0BA9CE6-CD4D-4770-B1D2-6A6D40495765Q35474529-069B26C1-D7FB-4FB8-AE3A-1A4A264F5CEAQ35474529-39648B42-4DAD-423C-900F-84A756B02CADQ35525184-49CF7027-DC73-4675-A11A-F771E73DF54DQ35542078-09F92184-B3D6-4F04-9F9B-4B454337F44CQ35689673-5895AAE9-79AF-491B-8FDE-6FC296F91E2EQ35915675-285154D7-B6C1-4433-9AFE-04DDB7ADFE81Q36022696-5817C862-C803-41DC-A2CE-FA0F9A875F88Q36191943-D31F7F10-E687-4651-9E85-922B485FD773Q36314775-5DC702FA-4725-4987-A880-C8D4F38F33D2Q36460093-41DCF016-4B7F-4B2D-8874-ECAE7A4FB1FDQ37212341-976A5268-0054-48DA-BB90-1A43A293DC3FQ37385234-E3587440-ECDA-40C5-B46F-9DE7B9A2B5D2Q37404111-41B6C7AC-E169-46A9-B258-8B240DFCAC46Q37421271-B550C6BD-5E25-4DD4-829F-8A3119FDCB3EQ37644788-72D34B80-5799-4D02-9A44-E3EDBD49B493
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gianni Bisogno
@ast
Gianni Bisogno
@en
Gianni Bisogno
@es
Gianni Bisogno
@nl
type
label
Gianni Bisogno
@ast
Gianni Bisogno
@en
Gianni Bisogno
@es
Gianni Bisogno
@nl
prefLabel
Gianni Bisogno
@ast
Gianni Bisogno
@en
Gianni Bisogno
@es
Gianni Bisogno
@nl
P1053
K-9282-2016
P106
P1153
7003672935
P31
P496
0000-0003-4462-5523